Lund, Sweden, December 20, 2013 - Active Biotech (NASDAQ OMX NORDIC: ACTI)
announced today that its collaboration partner Teva Pharmaceutical Industries
has been notified that The Committee for Medicinal Products for Human Use (CHMP)
of the European Medicines Agency (EMA) has not reached a final decision for
laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS).
It is anticipated that the CHMP will issue an opinion at its January, 2014
For further information, please contact:
Phone: +46 (0)46 19 20 95
Phone: +46 (0)46 19 20 44
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. In pivotal phase is
laquinimod, an orally administered small molecule with unique immunomodulatory
properties for the treatment of multiple sclerosis. Also tasquinimod for the
treatment of prostate cancer, with a unique mode of action, is in pivotal phase.
In addition, laquinimod has concluded Phase II development for Crohn's and
Lupus. The company has two additional projects in clinical development, ANYARA
primarily for the treatment of renal cell cancer and the orally administered
compound paquinimod (57-57) for systemic sclerosis. Please visit
www.activebiotech.com for more information.
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00
Active Biotech is obligated to publish the information contained in this press
release in accordance with the Swedish Securities Market Act. This information
was provided to the media for publication 1:10 p.m. CET on December 20, 2013.
Laquinimod CHMP/EMA Opinion:
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via GlobeNewswire